Anupam Kher is the new FTII chairman, replaces Gajendra Chauhan

Patna, Jul 29: BJP MLA Neeraj Kumar Singh Bablu, cousin of Sushant Singh Rajput, on Tuesday said that a huge amount of money has been transferred into the account of actress Rhea Chakraborty from the actor's account.

"An FIR has been filed against actress Rhea Chakraborty by the father of Sushant Singh as a huge amount of money has been transferred into her account and they both have joint accounts for some companies through which cheating has been done from her side," Bablu said.

"This is the issue of probe and police will go there and investigate the matter after that everything will be revealed," he added.

He also said that Karan Johar should also be called in for questioning by the Mumbai Police in connection with Sushant Singh Rajput's death case.

The statement was given in the backdrop of several top film personalities being questioned in connection with the case.

On July 28, an FIR has been registered against actor Rhea Chakraborty under various sections including abetment of suicide on the complaint of Sushant Singh Rajput's father Krishna Kishor Singh, the police said on Tuesday.

It said that a four-member team has been sent to Mumbai following registration of FIR.
"A four-member team has been sent to Mumbai. The team will collect case diary and other important documents from Mumbai Police," Sanjay Singh, Inspector General, Patna Central Zone said.

In the complaint made to Rajeev Nagar police station in-charge, KK Singh alleged that Rhea Chakraborty and her relatives "committed fraud" and "pressurised the actor for financial gains".

Sushant's father alleged that Chakraborty "got in touch with the actor with a motive to establish herself in the film industry using his contacts and she and her relatives started interfering in his affairs".

If everything goes as Russia’s expectation, it will be world’s first country to approve a coronavirus vaccine for widespread in the second week of August despite safety and efficacy concerns, according to a report. The adenoviral vector-based vaccine developed by Russian military and government researchers is currently in phase 2 trials.

According to a report from CNN, Russian officials are hoping to get approval for the COVID-19 vaccine developed by the Moscow-based Gamaleya Institute on Agust 10 or even before that. The officials told the outlet that the vaccine will be approved for public use with frontline healthcare workers receiving it first.

“It’s a Sputnik moment,” said Kirill Dmitriev, head of Russia’s sovereign wealth fund, which is financing Russian vaccine research, referring to the successful 1957 launch of the world’s first satellite by the Soviet Union, according to CNN.

“Americans were surprised when they heard Sputnik’s beeping. It’s the same with this vaccine. Russia will have got there first,” he was quoted as saying.

However, Russia is yet to release the scientific data on its coronavirus vaccine trials, hence, questions remain about the safety and efficacy of the vaccine, said the report. The vaccine is in the second phase of testing with developers planning to launch the phase 3 trials sometime after August 3.

Earlier, Interfax reported, citing Health Minister Mikhail Murashko, that the vaccine will be widely used in parallel with phase 3 trials. He said the country plans to vaccinate medics who are at high-risk for COVID-19 next month before clinical trials are completed.

Murashko added that individuals at higher risk of getting infected with the coronavirus such as older people or those with health conditions will also be prioritised for the vaccine, although he did not estimate or reveal when that would happen. The minister added 800 people will be recruited for the phase 3 trials.

Meanwhile, health officials were more cautious considering the fact that human testing of the vaccine is incomplete, and the state registration is expected to begin after August 3, reported The Moscow Times.

On Monday, Moderna and Pfizer announced the commencement of the final phase 3 trials of their candidate vaccines against the SARS-CoV-2 virus, which has so far claimed at least 654,477 lives and infected 16,514,500 people worldwide. 

Researchers will recruit up to 30,000 volunteers in separate trials both backed by the US government. India's first indigenous coronavirus vaccine, COVAXIN, is undergoing phase 1 human clinical trials across the country. More than 150 COVID-19 vaccines are being developed all over the world with at least six candidates already in late-stage clinical trials.